We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration Helps Accelerate Launch of New Malaria Test

By LabMedica International staff writers
Posted on 07 Feb 2016
Print article
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).
The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean principles” experts.

The accelerated product transfer and launch of the innovative “illumigene Malaria” test by Meridian Bioscience, Inc. (Cincinnati, OH, USA) was facilitated by collaboration with Lean Continuous Improvements, LLC (LCI; Cincinnati, OH, USA), a consulting firm expert in applying “lean principles” in conjunction with project management, to help minimize wasted time while maximizing product quality, and to facilitate team energy and conflict resolution. Meridian recognized a need to streamline the tasks and activities required to move its new test from product development phase through to final regulatory approval, and ultimately to clinical laboratories.

John A. Kraeutler, Chairman of the Board & CEO, Meridian, said, “The development of diagnostic tests is a highly complex process that involves multiple operating departments within Meridian. For us to achieve the highest efficiency in product transfer without sacrificing quality, we knew that we needed outside assistance. The team at LCI has a deep background in “Lean Transformation,” having worked with many diverse companies in many diverse areas such as Health Care, Lean Accounting, Product Development, Manufacturing, Supply Chain, and Total Maintenance. Our collaboration on the malaria test launch was a true partnership in which Meridian’s product-transfer team worked hand-in-hand with our LCI consultant to achieve a 3-month improvement in the final timeline. By increasing ownership, the team became a more disciplined, cohesive group.”

Gregory Battle, president and CEO of LCI, said, “The Meridian Bioscience C-Suite management team gave us great support all the way through the project. Lean Transformation is a ‘Systems’ approach designed so that clear standards are established and hidden problems surface, are identified, and resolved. With Lean Transformation, solutions are not ‘implemented,’ but rather problems are solved.”

He continued: “We start with grasping the situation where the work is done. We identify a problem area—a key business challenge with opportunities to demonstrate lean as a transformational system. [...] Leadership is the key for success; the top leaders within the facility must be actively, visibly involved in the vision-setting session and implementation.”

Related Links:

Meridian Bioscience
illumigene Malaria


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.